BioCentury | Sep 25, 2020
Finance

With inaugural fund, Pureos looks to build up Swiss biotech ecosystem

...of the Swiss Biotech Association since 2013 and previously founded and led Swiss antibody play ESBATech AG...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

...expects to launch brolucizumab this year and gained the mAb via its 2009 acquisition of ESBATech AG...
BioCentury | Oct 10, 2016
Company News

Novartis pharmaceuticals news

...positions in Basel. The pharma plans to close a biologics group in Shanghai and its ESBATech AG...
BioCentury | Oct 5, 2016
Company News

Novartis unveils NIBR reorganization

...said. The pharma plans to close a biologics group in Shanghai, as well as its ESBATech AG...
BioCentury | Sep 15, 2014
Clinical News

DLX105 topical: Phase II data

...of Alcon Inc. Alcon gained ophthalmic rights to the product through its 2009 acquisition of ESBATech AG...
BioCentury | May 30, 2011
Finance

Europe's Iceberg 2011: Unlocking hidden value

...So there are both early and late-stage opportunities. And in between there are things like ESBATech."...
...the T-Spot.TB test for tuberculosis. In September 2009, Alcon Inc. acquired the ophthalmic applications of ESBATech AG...
...Crucell N.V. Johnson & Johnson (NYSE:JNJ) $2,400 2008 Speedel Novartis AG (NYSE:NVS; SIX:NOVN) $1,000 2009 ESBATech AG...
BioCentury | May 4, 2011
Financial News

Delenex extends A round, adding $19.2 million

...Thomas Dyrberg will join Delenex's board. Delenex was spun out of EsbaTech AG in 2009 when EsbaTech...
BioCentury | Mar 7, 2011
Company News

OctoPlus, Alcon deal

...OctoPlus will develop a controlled-release formulation of an undisclosed biologic from Alcon's ESBATech AG research unit for...
...its PolyActive drug delivery technology. OctoPlus is responsible for preclinical testing and process development, while ESBATech...
BioCentury | Dec 13, 2010
Emerging Company Profile

Delenex: Fragments, Take Two

...exit after 11 years and $72 million in investment. The company is a spinout from ESBATech AG...
...and a lead candidate that's already shown proof of concept, albeit in a different indication. ESBATech...
...21, 2009) . Following the deal, the investors spun out Delenex with exclusive rights to ESBATech's...
BioCentury | Nov 13, 2010
Financial News

Delenex raises CHF13.5 million

...HBM BioVentures; BioMedInvest; and VI Partners. Delenex was spun out of EsbaTech AG in 2009 when EsbaTech...
Items per page:
1 - 10 of 52
BioCentury | Sep 25, 2020
Finance

With inaugural fund, Pureos looks to build up Swiss biotech ecosystem

...of the Swiss Biotech Association since 2013 and previously founded and led Swiss antibody play ESBATech AG...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

...expects to launch brolucizumab this year and gained the mAb via its 2009 acquisition of ESBATech AG...
BioCentury | Oct 10, 2016
Company News

Novartis pharmaceuticals news

...positions in Basel. The pharma plans to close a biologics group in Shanghai and its ESBATech AG...
BioCentury | Oct 5, 2016
Company News

Novartis unveils NIBR reorganization

...said. The pharma plans to close a biologics group in Shanghai, as well as its ESBATech AG...
BioCentury | Sep 15, 2014
Clinical News

DLX105 topical: Phase II data

...of Alcon Inc. Alcon gained ophthalmic rights to the product through its 2009 acquisition of ESBATech AG...
BioCentury | May 30, 2011
Finance

Europe's Iceberg 2011: Unlocking hidden value

...So there are both early and late-stage opportunities. And in between there are things like ESBATech."...
...the T-Spot.TB test for tuberculosis. In September 2009, Alcon Inc. acquired the ophthalmic applications of ESBATech AG...
...Crucell N.V. Johnson & Johnson (NYSE:JNJ) $2,400 2008 Speedel Novartis AG (NYSE:NVS; SIX:NOVN) $1,000 2009 ESBATech AG...
BioCentury | May 4, 2011
Financial News

Delenex extends A round, adding $19.2 million

...Thomas Dyrberg will join Delenex's board. Delenex was spun out of EsbaTech AG in 2009 when EsbaTech...
BioCentury | Mar 7, 2011
Company News

OctoPlus, Alcon deal

...OctoPlus will develop a controlled-release formulation of an undisclosed biologic from Alcon's ESBATech AG research unit for...
...its PolyActive drug delivery technology. OctoPlus is responsible for preclinical testing and process development, while ESBATech...
BioCentury | Dec 13, 2010
Emerging Company Profile

Delenex: Fragments, Take Two

...exit after 11 years and $72 million in investment. The company is a spinout from ESBATech AG...
...and a lead candidate that's already shown proof of concept, albeit in a different indication. ESBATech...
...21, 2009) . Following the deal, the investors spun out Delenex with exclusive rights to ESBATech's...
BioCentury | Nov 13, 2010
Financial News

Delenex raises CHF13.5 million

...HBM BioVentures; BioMedInvest; and VI Partners. Delenex was spun out of EsbaTech AG in 2009 when EsbaTech...
Items per page:
1 - 10 of 52